<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990310</url>
  </required_header>
  <id_info>
    <org_study_id>CORT113176-651</org_study_id>
    <secondary_id>2021-002544-78</secondary_id>
    <nct_id>NCT04990310</nct_id>
  </id_info>
  <brief_title>Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants</brief_title>
  <official_title>An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-CORT113176 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the mass balance recovery and metabolite profile, and will identify&#xD;
      metabolite structures following a single oral dose of [14C]-CORT113176 in healthy male&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 18, 2021</start_date>
  <completion_date type="Anticipated">October 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance Recovery in Excreta After a Single Dose of [14C]-CORT113176</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mass Balance Recovery in Urine After a Single Oral Dose of [14C]-CORT113176</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mass Balance Recovery in Feces After a Single Oral Dose of [14C]-CORT113176</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CORT113176 Metabolites Accounting for ≥10% of Total Circulating Radioactivity or ≥10% of Dose Excreted in Urine and Feces</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Total Radioactivity after Oral Dosing: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Total Radioactivity after Oral Dosing: Time from Dosing to Cmax (Tmax)</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Total Radioactivity after Oral Dosing: Area Under the Plasma Concentration-time Curve from Zero Time to Time of the Last Measurable Concentration (AUC0-last)</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Total Radioactivity after Oral Dosing: Apparent Elimination Half-life (t1/2)</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT113176 after Oral Dosing: Cmax</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT113176 after Oral Dosing: Tmax</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT113176 after Oral Dosing: AUC0-last</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT113176 after Oral Dosing: t1/2</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Total Radioactivity into Red Blood Cells after Oral Dosing</measure>
    <time_frame>Before dosing and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with One or More Adverse Events</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Study Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, participants will receive a single oral dose of [14C]-CORT113176 450 mg (3 X 150 mg lipid formulation capsules) in the fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-CORT113176</intervention_name>
    <description>[14C]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.</description>
    <arm_group_label>Study Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index 18.0 to 30.0 kg/m^2, inclusive&#xD;
&#xD;
          -  Willing and able to participate in the whole study&#xD;
&#xD;
          -  Have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per&#xD;
             day)&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Adhere to the contraception requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received any investigational medicine in a clinical research study within 90 days&#xD;
&#xD;
          -  Are, or are immediate family members of, a study site or sponsor employee&#xD;
&#xD;
          -  Evidence of current severe acute respiratory syndrome (SARS-CoV-2) infection&#xD;
&#xD;
          -  History of any drug or alcohol abuse, or regularly consume &gt;21 units alcohol per week&#xD;
&#xD;
          -  Current smoker or user of e-cigarettes and nicotine replacement products within the&#xD;
             last 6 months&#xD;
&#xD;
          -  Have pregnant or lactating partners&#xD;
&#xD;
          -  Radiation exposure, exceeding 5 milliSieverts (mSv) in the last 12 months or 10 mSv in&#xD;
             the last 5 years&#xD;
&#xD;
          -  Clinically significant abnormal results of clinical chemistry, hematology or&#xD;
             urinalysis as judged by the investigator&#xD;
&#xD;
          -  Confirmed positive drugs of abuse test result&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) antibody results&#xD;
&#xD;
          -  Active renal and/or hepatic disease&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, dermatological,&#xD;
             chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric&#xD;
             disorder&#xD;
&#xD;
          -  Any form of cancer within the last 5 years (exceptions apply)&#xD;
&#xD;
          -  History and/or symptoms of adrenal insufficiency&#xD;
&#xD;
          -  Condition that could be aggravated by glucocorticoid antagonism or activation&#xD;
&#xD;
          -  Donation of blood or plasma or loss of greater than 400 mL of blood within the&#xD;
             previous 3 months&#xD;
&#xD;
          -  Are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies&#xD;
             (other than up to 4 g of paracetamol per day) within 14 days. COVID-19 vaccines are&#xD;
             accepted concomitant medications. Exceptions may apply on a case by case basis.&#xD;
&#xD;
          -  Currently using glucocorticoids or have a history of systemic glucocorticoid use at&#xD;
             any dose within the last 12 months or 3 months for inhaled products&#xD;
&#xD;
          -  Additional criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazel Hunt, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hazel Hunt, Ph.D.</last_name>
    <phone>+1 650-688-2862</phone>
    <email>hhunt@corcept.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corcept Therapeutics</last_name>
    <phone>+1 650-327-3270</phone>
    <email>clinicalstudies@corcept.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

